Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) ---- Continuing enrollment ...

Fourth Quarter and Recent Business Highlights: KALA’s innovative pipeline is based on its proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA believes the multifactorial mechanism ...

MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative”, "BRTX” or the "Company”) ...

Previously, the Company was licensed by the NYSDOH to act as a tissue bank for the processing of mesenchymal stem cells derived from ... is a cell-based secretome containing exosomes, proteins ...

Such effect has been reported previously on murine mesenchymal stromal/stem cells derived from bone marrow and rat CSF ... This potentially suggests a role of CSF in modulating NSC secretome, which ...